6.
Bayat Mokhtari R, Homayouni T, Baluch N, Morgatskaya E, Kumar S, Das B
. Combination therapy in combating cancer. Oncotarget. 2017; 8(23):38022-38043.
PMC: 5514969.
DOI: 10.18632/oncotarget.16723.
View
7.
Liu Q, Hu Z, Jiang R, Zhou M
. DeepCDR: a hybrid graph convolutional network for predicting cancer drug response. Bioinformatics. 2020; 36(Suppl_2):i911-i918.
DOI: 10.1093/bioinformatics/btaa822.
View
8.
Menden M, Wang D, Mason M, Szalai B, Bulusu K, Guan Y
. Community assessment to advance computational prediction of cancer drug combinations in a pharmacogenomic screen. Nat Commun. 2019; 10(1):2674.
PMC: 6572829.
DOI: 10.1038/s41467-019-09799-2.
View
9.
Rafique R, Islam S, Kazi J
. Machine learning in the prediction of cancer therapy. Comput Struct Biotechnol J. 2021; 19:4003-4017.
PMC: 8321893.
DOI: 10.1016/j.csbj.2021.07.003.
View
10.
Nag S, Baidya A, Mandal A, Mathew A, Das B, Devi B
. Deep learning tools for advancing drug discovery and development. 3 Biotech. 2022; 12(5):110.
PMC: 8994527.
DOI: 10.1007/s13205-022-03165-8.
View
11.
Shorten C, Khoshgoftaar T, Furht B
. Text Data Augmentation for Deep Learning. J Big Data. 2021; 8(1):101.
PMC: 8287113.
DOI: 10.1186/s40537-021-00492-0.
View
12.
Seo H, Tkachuk D, Ho C, Mammoliti A, Rezaie A, Madani Tonekaboni S
. SYNERGxDB: an integrative pharmacogenomic portal to identify synergistic drug combinations for precision oncology. Nucleic Acids Res. 2020; 48(W1):W494-W501.
PMC: 7319572.
DOI: 10.1093/nar/gkaa421.
View
13.
LOEWE S
. The problem of synergism and antagonism of combined drugs. Arzneimittelforschung. 1953; 3(6):285-90.
View
14.
Ratner A, Ehrenberg H, Hussain Z, Dunnmon J, Re C
. Learning to Compose Domain-Specific Transformations for Data Augmentation. Adv Neural Inf Process Syst. 2018; 30:3239-3249.
PMC: 5786274.
View
15.
Pu L, Singha M, Ramanujam J, Brylinski M
. CancerOmicsNet: a multi-omics network-based approach to anti-cancer drug profiling. Oncotarget. 2022; 13:695-706.
PMC: 9119687.
DOI: 10.18632/oncotarget.28234.
View
16.
Ruiz R, Raez L, Rolfo C
. Entinostat (SNDX-275) for the treatment of non-small cell lung cancer. Expert Opin Investig Drugs. 2015; 24(8):1101-9.
DOI: 10.1517/13543784.2015.1056779.
View
17.
Cao H, Tan V, Pang J
. A parsimonious mixture of Gaussian trees model for oversampling in imbalanced and multimodal time-series classification. IEEE Trans Neural Netw Learn Syst. 2014; 25(12):2226-39.
DOI: 10.1109/TNNLS.2014.2308321.
View
18.
Szklarczyk D, Santos A, von Mering C, Jensen L, Bork P, Kuhn M
. STITCH 5: augmenting protein-chemical interaction networks with tissue and affinity data. Nucleic Acids Res. 2015; 44(D1):D380-4.
PMC: 4702904.
DOI: 10.1093/nar/gkv1277.
View
19.
Cazzaniga M, Camerini A, Addeo R, Nole F, Munzone E, Collova E
. Metronomic oral vinorelbine in advanced breast cancer and non-small-cell lung cancer: current status and future development. Future Oncol. 2015; 12(3):373-87.
DOI: 10.2217/fon.15.306.
View
20.
Smyth L, Tamura K, Oliveira M, Ciruelos E, Mayer I, Sablin M
. Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with -Mutant, ER-Positive Metastatic Breast Cancer. Clin Cancer Res. 2020; 26(15):3947-3957.
PMC: 7415507.
DOI: 10.1158/1078-0432.CCR-19-3953.
View